Therapeutic Potential of Vitamin D in Depressive Disorder and Anxiety Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 15 May 2024 | Viewed by 133
Special Issue Editor
Interests: animal models; neuroscience; behavioral pharmacology; neuropsychopharmacology; biological psychiatry; antidepressant agents
Special Issue Information
Dear Colleagues,
Over the last two decades, the critical role of vitamin D in brain development and function has been highlighted. This neurosteroid has been implicated in proliferation, differentiation, maturation, and neuronal survival. In addition, its neuromodulatory properties on serotoninergic, glutamatergic, and dopaminergic neurotransmission have also been reported, and its neuroprotective effects related to anti-inflammatory and antioxidant functions have been the subject of extensive research. Particularly, vitamin D deficiency, a condition that affects a high percentage of global population, has been investigated as a risk factor for depression and anxiety. In this regard, several studies have examined the potential of vitamin D as an antidepressant and anxiolytic strategy. However, the mechanisms underlying the antidepressant and anxiolytic effects of vitamin D have not yet been fully elucidated. In this context, this Special Issue aims to highlight innovative studies investigating the possible mechanisms underlying the beneficial effects of vitamin D for depression and anxiety. Additionally, original research articles and review papers dealing with the efficacy of vitamin D supplementation for the treatment of depression and anxiety disorders are welcome.
Prof. Dr. Ana Lúcia Severo Rodrigues
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antidepressant
- anxiety
- cholecalcipherol
- depression
- major depressive disorder
- vitamin D
